PDF(755 KB)
呼和浩特某三甲医院骨科门诊超说明书用药调查及相关不良事件分析
王楠楠, 石秀兰, 邵艳清, 张文兴
中国医院药学杂志 ›› 2016, Vol. 36 ›› Issue (22) : 2019-2023.
PDF(755 KB)
PDF(755 KB)
呼和浩特某三甲医院骨科门诊超说明书用药调查及相关不良事件分析
Analysis of off-label drug use and related adverse drug events in orthopedics outpatient prescriptions in a tertiary class A hospital
目的：分析呼和浩特某三级甲等医院骨科门诊超说明书用药情况，探讨其与临床不良反应/事件的关系，为超说明书用药管理提供参考依据。方法：采用回顾性分析方法，分层随机抽取该院2015年1-12月骨科门诊处方，分类统计超说明书用药类型，结合循证医学报道分析超说明书用药可行性。汇总分析因超说明书用药诱发的不良反应/事件，与同期上报的不良反应发生率相比较。结果：该院骨科门诊超说明书处方比例为9.88%。在用药类型方面以超剂量（疗程）用药（57.42%）最多；在用药科室方面以骨科专家门诊超说明书用药比例（44.26%）最高。所有超说明书用药中仅有8.97%（32/357）有循证医学证据。该院可追踪的因超说明书用药诱发药品不良事件13例次，发生比例为4.76%（13/273）。结论：骨科门诊超说明书用药现象普遍存在，相关各方面应引起重视并加以管理规范，以减少不良事件发生，促进临床合理用药。
OBJECTIVE To analyze off-label drug use and adverse drug events (ADE) in orthopedics outpatient prescriptions in a tertiary class A hospital in Huhhot.METHODS Prescriptions of orthopedics outpatients were randomly selected from January to December 2015. Off-label drug uses of each prescription were assessed and categorized according to drug specifications, and rationality of drug use was determined by referring to dispensatories and evidences. ADEs caused by off-label drug use were analyzed and compared with incidence of ADEs reported in this hospital.RESULTS Prevalence of off-label drug use in orthopedics outpatient prescriptions was 9.88%. Primary type of off-label drug use was over dose (57.42%), mostly occurred in aspecialist outpatient department (44.26%). Within all off-label drug uses, only 8.97% (32/357) prescriptions were evidence-based, and 4.76% (13/273) of total off-label drug use prescriptions induced ADE.CONCLUSION Off-label drug use generally exists in orthopedics outpatient prescriptions of this hospital. Further interventions should be adopted to promote drug rational use.
超说明用药 / 门诊 / 骨科 / 药品不良事件 {{custom_keyword}} /
off-label drug use / outpatient department / orthopedics / adverse drug events {{custom_keyword}} /
[1] 邵振, 卢军锋. 超药品说明书用药的相关法律责任问题研究[J]. 中国卫生法制, 2010, 19(6):16-19.
[2] 广东省药学会.关于印发《药品未注册用法专家共识》的通知[J]. 今日药学, 2010, 20(4):2.
[3] Kesselheim AS, Mello MM,Studdert DM.Strategies and practices in off-label marketing of pharmaceuticals:aretrospective analysis of whistleblower complaints[J]. PLoS Med, 2011, e10004318(4):1-9.
[4] Conti RM, Bernstein AC, Villaflor VM, et al. Prevalence of off-label use and spending in 2010 among patent-protected chemotherapies in a population-based cohort of medical oncologists[J]. J Clin Oncol, 2013, 31(9):1134-1139.
[5] 陈永法,黄丽. 我国超说明书用药现象探析[J]. 中国药房,2013, 24(13):1162-1164.
[6] 王健,陈燕华. 我院门诊2013年7-12月超说明书用药及典型处方分析[J]. 中国药房, 2015, 26(8):1041-1043.
[7] Wang WL, Zhu M, Guo DH, et al. Off-label and off-NCCN guidelines uses of antineoplastic drugs in China[J]. Iran J Public Health, 2013, 42(5):472-479.
[8] 陈迹, 闫波, 李桂荣, 等. 对住院医嘱静脉药物超说明书用药分析[J]. 中国医院药学杂志, 2014, 34(13):1118-1121.
[9] 刘皈阳, 王心慧, 陈召红. 超说明书用药问题的相关分析与思考[J]. 中国药物应用与监测, 2013, 10(3):123-127.
[10] 徐梦丹, 周碧霞, 党丽娟, 等. 医院门诊处方超说明书用药的调查分析[J]. 中国医药导报, 2014, 11(1):100-104.
[11] 谭谩. 某院2011-2012年门诊患者超说明书用药分析[J]. 中国药房, 2013, 24(38):3574-3577.
[12] 赖祥林. 活血化淤法在骨科的临床应用新进展[J]. 中国中医骨伤科杂志, 2005, 13(2):59-63.
[13] 江恒, 郭广波, 代震宇, 等. 红花黄色素注射液联合物理疗法治疗下肢深静脉血栓形成早期疗效观察[J]. 中国中医急症, 2014, 23(8):1508-1509.
[14] 韩进庭. 红花黄色素在髋关节置换术后预防下肢静脉血栓中的应用[J]. 中国实用医药,2013,8(26):192-193.
[15] 倪毅, 沈军, 刘遵勇, 等. 丹参多酚酸盐预防下肢骨折术后深静脉血栓的疗效观察[J]. 中国中医骨伤科杂志, 2015, (3):28-30.
[16] 李曙明, 彭文学, 杜恒, 等. 氨酚羟考酮片用于骨科严重背痛的临床评价[J]. 中国新药杂志, 2009, 18(20):1972-1974.
[17] Bekhit MH. Profile of extended-release oxycodone/acetaminophen for acute pain[J]. J Pain Res, 2015, 8:719-728.
内蒙古医科大学第二附属医院院基金支持项目（编号：2015YJJ18）
/
| 〈 |
|
〉 |
